What eMedica is, precisely
eMedica is a non-invasive bioelectronic medical device made by Rohera Healthcare & Technology Private Limited in Pune, India, and invented by Hemant K. Rohera, who is the named inventor on US patent 12,226,183 B2. It applies controlled combinations of voltage, current and frequency through electrodes placed on the skin, and it is licensed in India as a Class A medical device. It is intended as an adjuvant — used alongside prescribed care, not instead of it.
That paragraph is the whole answer. The rest of this page is the detail behind each part of it, because "bioelectronic device" is a phrase that can mean almost anything, and because several other organisations use a similar name. What follows is what the documents say, with each document named so it can be checked.
Who makes it, and who invented it?
The manufacturer is Rohera Healthcare & Technology Private Limited, CIN U33309PN2020PTC194671, registered in Pune, Maharashtra. The CIN can be entered on the Ministry of Corporate Affairs portal, which returns the incorporation date, the registered office, the directors and the filing history.
The inventor named on the patent is me. I am also the founder and CTO of the manufacturer, which is why the disclosure line sits in the byline at the top of this page rather than in small type at the bottom. The patent is held by the individual inventor and not by the company — the assignee field on the granted US patent reads Individual, and what that means commercially is set out in a separate page.
What does the device physically do?
It is applied through electrodes placed on the skin. Nothing is implanted, nothing breaks the skin, no drug is delivered, and no ionising radiation is involved. In the taxonomy a regulator or a biomedical engineer would use, it belongs to the same broad family as transcutaneous electrical nerve stimulation (TENS), microcurrent therapy and pulsed electromagnetic field (PEMF) devices: non-invasive surface electrical stimulation.
Belonging to that family is a statement about the category, not about the results. Those modalities are not each other, their published results do not transfer between them, and none of their trial data is eMedica data.
What do voltage, current and frequency mean here?
The manufacturer's name for the approach is VCF — voltage, current, frequency. The three are independent settings, and the reason all three are named is that a description giving only one of them is incomplete.
| Parameter | What it is |
|---|---|
| Voltage | The electrical potential applied across the electrodes. |
| Current | The charge that actually flows into tissue. The device is designed to work in the microcurrent range. |
| Frequency | The rate at which the delivered signal alternates or pulses. |
The ranges that matter legally are the ones recited in claim 1 of the granted patent, and those are on the public record at the link above. A marketed operating window is a different thing from a claimed range, and this page does not present one as the other.
What is the proposed mechanism — and how well established is it?
This is the question where most device copy goes wrong, so it is worth separating three things that are usually blended into one paragraph.
Established physiology. Cells maintain an electrical potential across their membranes, generated by ion gradients and the pumps and channels that sustain them. Endogenous electric fields exist in tissue and are measurable at wounds. This is textbook cell biology.
Published literature on the modality. Low-intensity electrical stimulation has been studied for tissue repair, pain modulation, local circulation and neuromuscular stimulation. That body of work is real but heterogeneous: sample sizes are frequently small, sham-controlling an electrical stimulus is methodologically hard, and results differ substantially between indications. Electrical stimulation for chronic wound healing and TENS for certain pain conditions have the strongest support; much of the rest remains investigational.
The manufacturer's proposed mechanism. According to the manufacturer's proposed mechanism, controlled VCF signals are intended to support normal cellular bioelectrical activity. This is a proposed mechanism. It is not an established finding for any particular use, and it is stated here as what the manufacturer proposes rather than as what has been demonstrated.
Keeping those three tiers visibly apart is the point. A paragraph of real physiology followed by "and that is what eMedica does" quietly promotes a manufacturer's hypothesis into textbook fact, and a reader who checks will find the seam. The honest construction is the one above: the biology is established, the modality literature is mixed, and the device's own mechanism is proposed.
What is it licensed as, and by whom?
eMedica is licensed in India as a Class A medical device under the Medical Devices Rules 2017. The manufacturing licence is MFG/MD/2023/000926, issued on Form MD-5 by the State Licensing Authority, Maharashtra. Class A is the lowest of the four risk classes in that framework.
Two further documents exist and are worth naming exactly, because each certifies something narrower than it is often taken to mean:
- ISO 13485:2016 — a quality management system certification. It certifies how the organisation documents and controls its processes. It says nothing about whether any device works.
- IEC 60601-1 — the general standard for basic safety of medical electrical equipment. Testing at a NABL-accredited laboratory recorded a patient leakage current of 1.3 µA against a 10 µA limit. That is a safety measurement of unintended current, not a measure of therapeutic output, and not evidence of benefit.
What eMedica is not
Not a cure, and not a treatment for any named condition. No claim of cure or of clinical efficacy is made here for any condition.
Not a replacement for prescribed treatment. It is adjuvant. Prescribed medication should be continued unless the treating physician changes it, and no one should change a regimen because of this device.
Not FDA approved, and not CE marked. There is no 510(k), De Novo or PMA, and no assessment under the EU Medical Device Regulation. It is not marketed in the United States. The FAQ page sets out the regulatory position in full.
Not supported by a published randomised controlled trial. None has been published. What a proper evidence pathway would require is described separately, and until that exists the honest label is the one used here.
Not the same organisation as the other eMedicas. Emedica Ltd of the United Kingdom is a GP examination training company and is unrelated. So are eMedica Technologies and the various eMedica-named health businesses. This device is made in Pune by the company named above.
Where is the patent, and where is it granted?
The underlying invention is Medical therapeutic device, application 17/753,643, priority from Indian application 201921036412 filed 10 September 2019, granted in the United States on 18 February 2025 as US 12,226,183 B2 with a term running to 5 May 2041.
Corresponding grants are on the registers of Japan (JP 7611901 B2), South Korea (KR 10-2954775), Australia (AU 2020346420 B2), Canada (CA 3150348), Saudi Arabia (SA 18122) and South Africa (ZA 2022/04073 B). Jurisdictions are named rather than counted here, deliberately: a count goes stale the moment one member of a family lapses, and the reader cannot check a number.
The European application EP 4041064 is under examination. That is an application, not a grant, and it confers nothing until and unless it is granted. The Indian application is likewise pending. The complete position, family by family, is on the patent register.
A patent is a finding on novelty, inventive step and industrial applicability. A patent office does not test whether a device works, and a granted patent is not evidence that it does. That distinction is worth repeating in a field where the two are routinely conflated.
Who should not use it?
Non-invasive surface electrical stimulation has a well-characterised general safety profile at therapeutic intensities, with mild and local effects — tingling, transient redness at the electrode site — the ones commonly reported. It is not appropriate for everyone. Physician clearance is required first, and in several cases the device should not be used at all, where the person:
- has an implanted electronic device — a cardiac pacemaker, implantable defibrillator, deep brain stimulator, cochlear implant or implanted pump;
- is pregnant, particularly for any application over the abdomen, lower back or pelvis;
- has an active malignancy, where nothing should be applied over a known tumour site without oncologist direction;
- has epilepsy or a seizure disorder, where application over the head and neck requires neurologist guidance;
- has a known or suspected deep vein thrombosis, or active thrombophlebitis;
- has a cardiac arrhythmia or unstable cardiac disease, without cardiology clearance.
Electrodes should not be placed over the carotid sinus or the front of the neck, across the eyes or the head, over broken or infected skin, or in any arrangement that would take current across the chest. Closer supervision is needed where sensation is impaired, since the person may not feel an intensity that is too high. Use should stop, and medical advice be sought, for increasing pain, a burn or persistent skin reaction, dizziness, palpitations or any new neurological symptom.
How is it meant to be used?
Under appropriate clinical supervision, as an adjuvant alongside prescribed medication, clinical protocols and medical procedures. Anyone using it should tell their treating physician that they are. Individual responses vary, and progress should be judged with that physician against the person's own clinical measures rather than against a timeline promised by a manufacturer.
References
US 12,226,183 B2, Medical therapeutic device — patents.google.com/patent/US12226183B2
Inventor record — Justia: Hemant Karamchand Rohera
Medical Devices Rules 2017 and device classification — Central Drugs Standard Control Organisation
ISO 13485:2016, Medical devices — Quality management systems — iso.org/standard/59752.html
IEC 60601-1, Medical electrical equipment — Part 1: General requirements for basic safety and essential performance — webstore.iec.ch/publication/2612
Laboratory accreditation — National Accreditation Board for Testing and Calibration Laboratories
Author identifier — ORCID 0009-0005-3275-1743
Disclosure. I am the inventor named on the eMedica patent and the founder and CTO of the manufacturer. I have a commercial interest in this device.
Not medical advice. This page describes a device and the documents that govern it. It is not medical advice, not a recommendation for treatment, and not a reason to change any prescribed treatment. eMedica is a non-invasive adjuvant device intended to be used alongside — not instead of — prescribed medication, clinical protocols and medical procedures. Continue prescribed medication unless your treating physician changes it, and consult a qualified healthcare professional before starting or changing any therapy. Individual results may vary.